We investigated the performance of the KDM approach against the benchmarks described in the experimentation section with different reward criteria for the HIV therapy selection task. We tested three alternative formulations of reward functions wherein, (a) a higher weight is placed on CD4 + counts than viral load, (b) CD8 + counts are included, (c) a higher weight is placed on the absolute number of mutations than both the CD4 + counts and viral load. These reward functions are given as follows:
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(a)
r t = −0.7 log V t + 0.6 log C t + 0.6 log E t − 0.2|M t |, if V t is above detection
where V t is the viral load (in copies/mL), C t is the CD4 + count (in cells/mL), E t is the CD8+
(cytotoxic T-cell) count (in cells/mL), and |M t | is the number of mutations at time t.
Our setup was identical to that described in the experimentation section, where the reward criterion was replaced by (a), (b) and (c) respectively. We tested the performance of KDM with the alternative reward criteria on the same held-out set of 3000 patients as before. These results are shown in the following S1 Table A ., S1 Table B . and S1 Table C . respectively. 1 S1 Table A . Performance comparison of KDM vs. baselines for HIV therapy selection across 3000 held-out patients using a POMDP model with 30 states using reward criterion (a). KDM still produces the largest immune response while reducing the viral load, regardless of whether a larger weight is given to CD4 + or V t . S1 Table B . Performance comparison of KDM vs. baselines for HIV therapy selection across 3000 held-out patients using a POMDP model with 30 states using reward criterion (b). KDM still produces the largest immune response when including cytotoxic T-cell counts E t in the reward criterion. S1 Table C . Performance comparison of KDM vs. baselines for HIV therapy selection across 3000 held-out patients using a POMDP model with 30 states using reward criterion (c). Performance of KDM has significantly higher variance when placing a higher weight on the number of mutations. Evidently in this case, KDM does not always lead to the best immune response.
These results show that the performance of KDM is reasonably robust against the relative weightings of immune response indicators, however placing a heavier negative weight on the ab-2 solute number of mutations results in higher variance in the results across all policies, including the other baseline policies. In this case, KDM does not always lead to the best immune response.
Since the number of mutations at each point is highly dependent on the number of strains infecting a patient at a time and past exposure to drugs, they can fluctuate considerably across patients. Normalising these counts or incorporating the mutations into a risk score(indicating the likelihood of resistance), rather than including an absolute count in the reward function may overcome this issue. Importantly however, all the methods appear to be sensitive to this choice.
